Tenaya Therapeutics, Inc. (TNYA)
0.6687
-0.03
(-4.10%)
USD |
NASDAQ |
Aug 24, 16:00
0.6687
0.00 (0.00%)
After-Hours: 20:00
Tenaya Therapeutics Enterprise Value : 82.22M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 82.22M |
| August 20, 2026 | 80.69M |
| August 19, 2026 | 85.72M |
| August 18, 2026 | 82.49M |
| August 17, 2026 | 82.85M |
| August 14, 2026 | 89.13M |
| August 13, 2026 | 90.22M |
| August 12, 2026 | 97.06M |
| August 11, 2026 | 94.33M |
| August 10, 2026 | 91.21M |
| August 07, 2026 | 88.83M |
| August 06, 2026 | 88.61M |
| August 05, 2026 | 101.82M |
| August 04, 2026 | 92.15M |
| August 03, 2026 | 89.33M |
| July 31, 2026 | 91.86M |
| July 30, 2026 | 94.04M |
| July 29, 2026 | 90.70M |
| July 28, 2026 | 95.40M |
| July 27, 2026 | 98.43M |
| July 24, 2026 | 99.64M |
| July 23, 2026 | 99.22M |
| July 22, 2026 | 102.78M |
| July 21, 2026 | 110.76M |
| July 20, 2026 | 109.33M |
| Date | Value |
|---|---|
| July 17, 2026 | 109.06M |
| July 16, 2026 | 113.68M |
| July 15, 2026 | 114.93M |
| July 14, 2026 | 119.73M |
| July 13, 2026 | 113.43M |
| July 10, 2026 | 121.03M |
| July 09, 2026 | 116.46M |
| July 08, 2026 | 123.16M |
| July 07, 2026 | 132.16M |
| July 06, 2026 | 119.91M |
| July 02, 2026 | 102.31M |
| July 01, 2026 | 93.12M |
| June 30, 2026 | 91.59M |
| June 29, 2026 | 88.70M |
| June 26, 2026 | 84.93M |
| June 25, 2026 | 83.30M |
| June 24, 2026 | 87.83M |
| June 23, 2026 | 86.77M |
| June 22, 2026 | 81.13M |
| June 18, 2026 | 87.77M |
| June 17, 2026 | 83.62M |
| June 16, 2026 | 76.79M |
| June 15, 2026 | 85.19M |
| June 12, 2026 | 83.69M |
| June 11, 2026 | 85.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.433B |
| Anavex Life Sciences Corp. | 172.83M |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Oncolytics Biotech, Inc. | 101.41M |
| Sangamo Therapeutics, Inc. | 50.70M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.39M |
| Revenue (Quarterly) | 1.11M |
| Total Expenses (Quarterly) | 44.50M |
| EPS Diluted (Quarterly) | -0.1994 |
| Gross Profit Margin (Quarterly) | -52.97% |
| Profit Margin (Quarterly) | -3.91K% |
| Earnings Yield | -78.90% |
| Normalized Earnings Yield | -67.76 |